Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Sanofi (SNY) over the last 7 years, with Q4 2025 value amounting to -$2.8 billion.

  • Sanofi's Cash from Investing Activities rose 3950.96% to -$2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.7 billion, marking a year-over-year increase of 14464.19%. This contributed to the annual value of -$14.5 billion for FY2025, which is 20442.55% down from last year.
  • As of Q4 2025, Sanofi's Cash from Investing Activities stood at -$2.8 billion, which was up 3950.96% from -$369.4 million recorded in Q3 2025.
  • Sanofi's Cash from Investing Activities' 5-year high stood at $10.8 billion during Q2 2025, with a 5-year trough of -$6.7 billion in Q4 2023.
  • Its 4-year average for Cash from Investing Activities is -$937.4 million, with a median of -$816.3 million in 2025.
  • The largest annual percentage gain for Sanofi's Cash from Investing Activities in the last 5 years was 42847.69% (2025), contrasted with its biggest fall of 10198.18% (2025).
  • Sanofi's Cash from Investing Activities (Quarter) stood at -$100.6 million in 2021, then plummeted by 6534.0% to -$6.7 billion in 2023, then grew by 29.4% to -$4.7 billion in 2024, then soared by 39.51% to -$2.8 billion in 2025.
  • Its last three reported values are -$2.8 billion in Q4 2025, -$369.4 million for Q3 2025, and $10.8 billion during Q2 2025.